KR20050007883A - Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives - Google Patents

Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives Download PDF

Info

Publication number
KR20050007883A
KR20050007883A KR1020030047504A KR20030047504A KR20050007883A KR 20050007883 A KR20050007883 A KR 20050007883A KR 1020030047504 A KR1020030047504 A KR 1020030047504A KR 20030047504 A KR20030047504 A KR 20030047504A KR 20050007883 A KR20050007883 A KR 20050007883A
Authority
KR
South Korea
Prior art keywords
composition
ascorbic acid
present
light damage
green tea
Prior art date
Application number
KR1020030047504A
Other languages
Korean (ko)
Inventor
이병래
Original Assignee
(주)현덕비엔티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)현덕비엔티 filed Critical (주)현덕비엔티
Priority to KR1020030047504A priority Critical patent/KR20050007883A/en
Priority to PCT/KR2004/001524 priority patent/WO2005004827A1/en
Publication of KR20050007883A publication Critical patent/KR20050007883A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2132—Other phenolic compounds, polyphenols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/708—Vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: Provided is a composition containing polyphenol purified from green tea, ascorbic acid or its derivatives. The composition has anti-photoxic effect on the skin. Therefore, the composition is used for cosmetics, foods and pharmaceuticals for inhibition of ultraviolet injury. CONSTITUTION: The composition having anti-photoxic effect on the skin is characterized by containing 50-95 parts by weight of green tea polyphenols, and 5-50 parts by weight of ascorbic acid or its derivatives. The polyphenol is selected from epigallocatechin gallate, epicatechin gallate, and epigallocatechin. And ascorbic acid or its derivative is selected from ascorbic acid, ascorbyl palmitate, calcium ascorbate, magnesium ascorbate and zinc ascorbate.

Description

녹차 폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는 피부 광 손상 방지용 조성물 {Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives}Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives}

본 발명은 피부 광(光) 손상 방지용 조성물에 관한 것이다.The present invention relates to a composition for preventing skin light damage.

햇빛 중의 자외선은 피부의 광 손상을 유발하여 피부의 미용 상태 및 피부 건강에 악영향을 미친다.Ultraviolet rays in the sunlight cause light damage to the skin, which adversely affects the beauty of the skin and the health of the skin.

광 손상이란 빛에 피부가 노출되었을 때 광 생물학적 반응을 일으켜 나타나는 현상으로, 빛에 노출된 후 바로 나타내는 급성 광 손상과 오랜 기간 빛에 노출되어 나타나는 만성 광 손상으로 구분된다. 만성 광 손상은 색소 침착이나 피부가 거칠어지는 현상 등의 광 노화 또는 피부암 등을 예로 들 수 있으며, 급성 광 손상은 광 화상 또는 색소침착 등을 예로 들 수 있다.Photodamage is a phenomenon that occurs when the skin is exposed to light and causes a photobiological response. It is classified into acute light damage immediately after exposure to light and chronic light damage caused by long-term light exposure. Chronic light damage may include light aging or skin cancer such as pigmentation or rough skin, and acute light damage may include light burn or pigmentation.

피부의 광 손상은 대부분 자외선이 침투되는 표피 층과 진피 상층에서 일어나는데, 자외선 조사에 의해 생성되는 산소 유리기는 자외선에 의한 색소의 침착, 노화 및 피부암발생 등 자외선에 의한 광 손상과 밀접한 연관이 있는 것으로 알려져 있다.Most of the light damage of the skin occurs in the epidermal layer and the upper layer of the dermis through which UV rays penetrate, and the oxygen free radicals generated by UV irradiation are closely related to the light damage caused by UV rays such as pigmentation by UV rays, aging and skin cancer. Known.

자외선 중에서 자외선 B(UVB;290-320 nm)는 자외선 중 광 생물학적으로 인체에 가장 영향을 많이 미치고 피부에 광 손상을 일으키는 주원인이며, 자외선 C(UVC;200-290 nm)는 세포를 파괴하는 힘이 매우 강하나 파장이 짧아 침투력이 미약하고, 자외선 A(UVA;320-400 nm)는 에너지 강도가 UVB의 1/1000 정도이므로 그 영향은 미미하다.Among the ultraviolet rays, ultraviolet B (UVB; 290-320 nm) is the major cause of photobiological damage to the human body and the most damaging effect on the skin, and ultraviolet C (UVC; 200-290 nm) is the force that destroys cells. Although very strong, the wavelength is short, the penetration power is weak, and the ultraviolet ray A (UVA; 320-400 nm) has an energy intensity of about 1 / 1000th of the UVB, so its effect is insignificant.

자외선에 의한 피부 광 손상을 막기 위한 방법의 일환으로, 자외선 차단제에 대한 연구가 꾸준히 이루어지고 있다. 현재까지 개발된 광 손상 방지제는 피부에 바르는 형태가 대부분으로, 화학적 또는 물리적으로 햇빛을 흡수, 분산, 또는 반사 시킴으로써 광의 흡수를 감소시킬 수 있는 제제가 이용되고 있다.As part of a method for preventing skin light damage caused by ultraviolet rays, research on sunscreens has been conducted steadily. Light damage preventing agents developed to date are mostly applied to the skin, and agents that can reduce light absorption by absorbing, dispersing, or reflecting sunlight chemically or physically are used.

기존에 개발된 자외선 차단제는 자외선의 침투를 차단하여 세포를 보호하는 작용이 있긴 하나, 자외선이 표피 층과 진피 상층에 침투된 이후의 세포손상작용은 전혀 억제할 수 없으므로 효율적인 광 손상 억제가 불가능하다. 자외선에 노출된 피부의 광 손상을 억제하는 효과적인 조성물에 대한 연구가 진행되고 있으나, 아직까지 그 결과는 미진하다.Although the previously developed sunscreens act to protect the cells by blocking the penetration of ultraviolet rays, it is impossible to effectively suppress the damage of cells after the UV rays penetrate into the epidermis and the dermis. . Research into an effective composition for suppressing light damage of the skin exposed to ultraviolet light, but the results are still insufficient.

한편 녹차는 폴리페놀, 카페인, 유리아미노산, 비타민 A, B1, B2, C, E 등의 비타민 류, 유리당 등 여러 가지 물질을 함유하며, 이들 중에서 특히 폴리페놀은 자외선에 의한 피부손상을 방지할 수 있다는 연구보고가 있었다(Elmets CA et al, Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol. 44:425-32, 2001; Katiyar SK et al, Green tea polyphenols:DNA photodamage and photoimmunology. J Photochem Photobiol B. 65:109-14. 2001; Vayalil PK et al: Treatment of green tea polyphenols in hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse skin. Carcinogenesis. 24:927-36. 2003).On the other hand, green tea contains various substances such as polyphenols, caffeine, free amino acids, vitamins such as vitamins A, B 1 , B 2 , C, E, and free sugars, among which polyphenols prevent skin damage caused by ultraviolet rays. (Elmets CA et al, Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol. 44: 425-32, 2001; Katiyar SK et al, Green tea polyphenols: DNA photodamage and photoimmunology. J Photochem Photobiol B. 65: 109-14. 2001; Vayalil PK et al: Treatment of green tea polyphenols in hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse skin.Carcinogenesis. 24: 927-36.2003).

그러나 녹차 폴리페놀은 끓는 물에서 30분 이상 우려내야 충분한 양이 추출되기 때문에 건조 녹차잎 분말을 직접피부에 바르는 정도의 조건에서는 유리되는 폴리페놀의 광 손상방지 효과는 미흡하다. 또한 녹차잎 전체 추출물이나 녹차 액기스도 분말로 만들었을 경우 폴리페놀의 함량이 낮기 때문에, 이론적으로 기대되는 수준의 효과를 실제 적용시 나타내기는 어렵다.However, since green tea polyphenol is extracted in boiling water for more than 30 minutes, sufficient amount is extracted, so that the effect of free light damage of polyphenol which is liberated under the condition that dry tea leaf powder is applied directly to the skin is insufficient. In addition, if the green tea leaf extract or green tea extract is made of powder, the content of polyphenol is low, so it is difficult to show the effect of theoretically expected level in actual application.

녹차가 포함하는 성분 중에서 광 손상 방지 효과를 나타낼 것으로 기대되는 또 다른 성분은 항(亢) 산화기능을 지닌 것으로 알려진 아스코르빈산이 있으나, 아스코르빈산은 열에 약하여 차잎의 가공과정과 열수 추출과정에서 대부분 파괴되므로, 녹차의 열수 추출물에는 최종적으로 매우 적은 양이 함유될 뿐이다.Another component of green tea that is expected to show the effect of preventing light damage is ascorbic acid, which is known to have anti-oxidative function. However, ascorbic acid is weak in heat, so it is difficult to process tea leaves and extract hot water. Since most are destroyed, the hydrothermal extract of green tea contains only a very small amount in the end.

그 외에도 항 산화기능을 지닌 비타민들로 이루어진 조성물, 또는 비타민을 주성분으로 하고 추가성분으로서 녹차 추출물을 극소량 함유하는 항산화 조성물들이 연구된 바 있다. 상기 조성물들은 주로 수용액 상태의 에멀젼 또는 크림 형태의 화장료 조성물로 제공되고 있다.In addition, a composition consisting of vitamins having an antioxidant function or antioxidant compositions containing a very small amount of green tea extract as a main ingredient and additional ingredients have been studied. The compositions are mainly provided as cosmetic compositions in the form of emulsions or creams in aqueous solution.

그러나 녹차 폴리페놀과 아스코빈산은 물에 용해시키면 시간의 경과와 함께 그 항 산화효과가 급격하게 감소하는 것으로 알려져 있다. 따라서 상기 수용액상태의 에멀션이나 크림형태의 조성물들로는 녹차 폴리페놀이나 아스코빈산에 의한 항 산화효과를 기대하기 어려우며, 결과적으로는 안정화된 물질 조성물과 비슷한 정도의 효과를 나타낼 뿐이다. 실제로 상기 조성물들의 항 산화효과는 기대한 수준에 미치지 못하는 실정이다.However, green tea polyphenols and ascorbic acid are known to rapidly decrease their antioxidant effects over time when dissolved in water. Therefore, it is difficult to expect the antioxidant effect of the green tea polyphenols or ascorbic acid in the emulsion or cream form of the aqueous solution state, and as a result only shows a similar effect to the stabilized material composition. Indeed, the antioxidant effects of the compositions do not meet expected levels.

반면 녹차의 폴리페놀을 주성분으로 하여 자외선에 의한 피부세포 독성을 억제할 수 있는 광 손상 방지용 조성물은 현재까지 공지된 바 없다.On the other hand, a light damage preventing composition capable of suppressing skin cell toxicity caused by ultraviolet rays using polyphenol as a main component has not been known until now.

이에, 본 발명자들은 녹차로부터 추출한 폴리페놀을 주성분으로 하여 아스코르빈산 또는 그 유도체를 최적의 비율로 추가하여 제조한 조성물 및 이를 이용하는 피부 광 손상 억제 방법을 개발함으로써, 본 발명을 완성하였다.Accordingly, the present inventors have completed the present invention by developing a composition prepared by adding ascorbic acid or a derivative thereof in an optimal ratio with polyphenol extracted from green tea as a main component and a method for inhibiting skin light damage using the same.

본 발명에서는 자외선에 의한 세포독성작용의 개시를 예방하고, 자외선 조사에 의해서 손상된 세포를 회복시킴으로써, 자외선에 의한 세포독성을 억제할 수 있는 피부 광 손상 방지용 조성물 및 이를 이용하는 피부 광 손상 억제 방법을 제공하고자 한다.The present invention provides a composition for preventing skin light damage and a method for inhibiting skin light damage using the same, by preventing the onset of cytotoxic action by ultraviolet light and restoring cells damaged by ultraviolet irradiation. I would like to.

본 발명은 녹차 폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는 피부 광 손상 방지용 조성물을 제공한다.The present invention provides a composition for preventing skin light damage containing green tea polyphenols and ascorbic acid or derivatives thereof.

본 발명의 피부 광 손상 방지용 조성물은 녹차로부터 추출한 폴리페놀 50∼95 중량부와 아스코르빈산 또는 그 유도체 5∼50 중량부로 이루어진다.The composition for preventing skin light damage of the present invention comprises 50 to 95 parts by weight of polyphenol extracted from green tea and 5 to 50 parts by weight of ascorbic acid or its derivatives.

본 발명의 피부 광 손상 방지용 조성물이 함유하는 폴리페놀은 에피갈로카테친 갈레이트(epigallocatechin gallate: 이하 EGCG라 한다), 에피카테친 갈레이트(epicatechine gallate), 에피갈로카테친(epigallocatechine) 중에서 선택된 하나 이상이 될 수 있다.The polyphenol contained in the composition for preventing skin light damage of the present invention is at least one selected from epigallocatechin gallate (hereinafter referred to as EGCG), epicatechin gallate and epigallocatechin. This can be

본 발명의 피부 광 손상 방지용 조성물이 함유하는 아스코르빈산 또는 그 유도체는 아스코르빈산(ascorbic acid), 아스코르빌 팔미테이트(ascorbyl palmitate), 칼슘 아스코르베이트(calcium ascorbates), 마그네슘 아스코르베이트(magnesium ascorbates) 및 아연 아스코르베이트(zinc ascorbates) 중에서 선택된 하나 이상이 될 수 있다.Ascorbic acid or a derivative thereof contained in the composition for preventing skin light damage of the present invention is ascorbic acid (ascorbic acid), ascorbyl palmitate, calcium ascorbates, calcium ascorbate ( It may be one or more selected from magnesium ascorbates and zinc ascorbates.

본 발명의 피부 광 손상 방지용 조성물은 자외선에 의한 세포독성을 억제한다.The composition for preventing skin light damage of the present invention inhibits cytotoxicity caused by ultraviolet rays.

본 발명의 피부 광 손상 방지용 조성물은 구체적으로 자외선에 의한 세포독성작용의 개시를 예방한다.The composition for preventing skin light damage of the present invention specifically prevents the onset of cytotoxic action by ultraviolet rays.

본 발명의 피부 광 손상 방지용 조성물은 구체적으로 자외선 조사에 의해서 손상된 세포를 회복시킨다.The composition for preventing skin light damage of the present invention specifically restores cells damaged by ultraviolet irradiation.

본 발명의 조성물은 화장료 조성물, 식품 조성물, 또는 약제학적 조성물로서 제공된다.The composition of the present invention is provided as a cosmetic composition, a food composition, or a pharmaceutical composition.

이하, 본 발명의 피부 광 손상 방지용 조성물의 제조방법에 대해 설명한다.Hereinafter, the manufacturing method of the composition for preventing skin light damage of this invention is demonstrated.

본 발명의 피부 광 손상 방지용 조성물이 함유하는 녹차 폴리페놀은 녹차로부터 폴리페놀을 추출, 분리, 정제할 수 있는 방법 중 어떤 것을 사용하여 제조하여도 무방하며, 그 예로 대한민국 등록특허공보 제 10-377313호에 기재되어 있는녹차 추출물의 제조방법을 들 수 있다.The green tea polyphenols contained in the composition for preventing skin light damage of the present invention may be prepared using any of methods for extracting, separating and purifying polyphenols from green tea, for example, Korean Patent Publication No. 10-377313 The manufacturing method of the green tea extract of description is mentioned.

상기 방법에서는 열풍건조한 녹차잎 분말 1 중량부에 5 내지 20 중량부의 물을 가하여 15분 내지 2시간 동안 가열한 후, 녹차잎 분말을 제거하고 냉각시켜 침전물을 제거한다. 수득된 추출액을 다시 가열한 후 냉각시켜 침전물을 제거하고, 건조시켜 녹차 폴리페놀 분말을 얻는다. 이때 가열온도는 60∼110℃인 것이 바람직하며, 건조방법은 분무건조법을 시행하는 것이 바람직하다.In the above method, 5-20 parts by weight of water is added to 1 part of hot-air dried green tea leaf powder, followed by heating for 15 minutes to 2 hours, and then the green tea leaf powder is removed and cooled to remove the precipitate. The obtained extract is heated again and then cooled to remove the precipitate and dried to obtain green tea polyphenol powder. At this time, the heating temperature is preferably 60 ~ 110 ℃, the drying method is preferably to carry out the spray drying method.

본 발명의 피부 광 손상 방지용 조성물이 함유하는 아스코르빈산 또는 그 유도체는 시판되는 제품 중 어떤 것을 사용하여도 무방하다.Ascorbic acid or a derivative thereof contained in the composition for preventing skin light damage of the present invention may be any of commercially available products.

상기와 같이 준비한 녹차 폴리페놀, 또는 아스코르빈산 또는 그 유도체를 각각 50∼95 중량부와 5∼50 중량부씩 혼합함으로써 본 발명의 조성물을 제조한다.The composition of the present invention is prepared by mixing 50 to 95 parts by weight and 5 to 50 parts by weight of green tea polyphenols or ascorbic acid or derivatives thereof prepared as described above.

본 발명의 조성물은 상기 성분들 뿐 아니라 이와 동일 또는 유사한 기능을 지닌 다른 유효성분을 추가로 함유할 수 있다.The composition of the present invention may further contain the above ingredients as well as other active ingredients having the same or similar functions.

또한 본 발명의 조성물은 상기 성분들과 상이한 기능을 지닌 다른 유효성분을 추가로 함유할 수도 있다.In addition, the composition of the present invention may further contain other active ingredients having different functions from the above components.

본 발명의 조성물을 화장료 조성물로 제공할 때는, 필요에 따라 보습제, 피부보호제, 점증제, 중화제, 가용화제, 방부제, 용제를 추가로 포함할 수 있다.When providing the composition of the present invention as a cosmetic composition, a moisturizer, skin protectant, thickener, neutralizing agent, solubilizer, preservative, solvent may be further included as necessary.

본 발명의 화장료 조성물은 섭취가 가능하도록 정제, 캡슐, 알약의 형태로 제제화되거나, 또는 피부에 적용할 수 있도록 패치, 크림, 겔, 연고, 에멀전 등의 고체 형태, 또는 용액, 현탁액, 로션, 혈청, 유제 등의 액체 형태로 제제화될 수 있으며, 필요에 따라 다른 제형으로 바꾸어 사용할 수도 있다.The cosmetic composition of the present invention may be formulated in the form of tablets, capsules, pills for ingestion, or in solid forms such as patches, creams, gels, ointments, emulsions, or solutions, suspensions, lotions, serums for application to the skin. It may be formulated in liquid form, such as emulsions, or may be used in other formulations as necessary.

본 발명의 화장료 조성물의 가장 바람직한 형태는 분말캡슐, 분말, 또는 마이크로캡슐이며, 상기와 같은 제형은 본 발명의 조성물이 함유하는 폴리페놀이 물과 직접 반응하여 광 손상 억제 효과가 급격히 감소하는 것을 막고, 사용하기 직전에만 물과 반응할 수 있도록 함으로써 광 손상 억제 효과를 극대화한다.The most preferred form of the cosmetic composition of the present invention is a powder capsule, a powder, or a microcapsule, and the above formulation prevents the polyphenols contained in the composition of the present invention from directly reacting with water, thereby rapidly decreasing the effect of inhibiting light damage. It also maximizes the effect of suppressing light damage by allowing it to react with water only immediately before use.

본 발명의 조성물을 식품 조성물로 제공할 때는, 필요에 따라 다양한 보조성분을 추가할 수 있다. 그 예로 아미노산, 탄수화물, 비타민(Vitamin)류와, 구리, 칼슘, 망간, 마그네슘, 칼륨, 아연 등의 미네랄, 유산균, 또는 효모생산물 등이 있다.When providing the composition of the present invention as a food composition, various auxiliary ingredients may be added as necessary. Examples include amino acids, carbohydrates, vitamins, minerals such as copper, calcium, manganese, magnesium, potassium, and zinc, lactic acid bacteria, or yeast products.

본 발명의 식품 조성물은 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 향미제로는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 들 수 있다. 천연 탄수화물로는 포도당, 과당 등의 단당류, 말토스, 수크로오스 등의 이당류, 덱스트린, 사이클로덱스트린 등의 다당류, 자일리톨, 소르비톨, 에리트리톨 등의 당알코올류 등이 들 수 있다.The food composition of the present invention may contain various flavors or natural carbohydrates and the like as additional ingredients, as in general food compositions. Flavoring agents include natural sweeteners such as taumartin and stevia extract, and synthetic sweeteners such as saccharin and aspartame. Natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol.

본 발명의 조성물을 약제학적 조성물로 제공할 때는 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제제화할 수 있다.When providing the composition of the present invention as a pharmaceutical composition, in addition to the active ingredient described above, it may be formulated to include one or more pharmaceutically acceptable carriers.

약제학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당분야의 적정한 방법으로, 또는 Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라, 또는 성분에 따라 바람직하게 제제화할 수 있다.Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components, if necessary, antioxidants, buffers, bacteriostatic agents, etc. Other conventional additives can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

본 발명의 약제학적 조성물의 제제 형태는 피부도포제, 액제, 분말제, 캡슐, 정제, 시럽 등의 형태로 제공되는 것이 바람직하며, 그외 산제, 과립제, 피복정, 탕제, 엑기스제, 좌제, 즙, 현탁제, 유제 또는 활성 화합물의 서방출형 제제 등으로 제공될 수도 있다.Formulation form of the pharmaceutical composition of the present invention is preferably provided in the form of skin coatings, solutions, powders, capsules, tablets, syrups, etc., and other powders, granules, coated tablets, baths, extracts, suppositories, juice, It may also be provided as a suspending agent, emulsion or sustained release formulation of the active compound.

본 발명의 약제학적 조성물의 투여량 또는 섭취량은 분말 제제의 경우 성인 1회당 사용량이 수백 ㎎ 내지 수 g 정도, 용액의 경우, 성인 1회당 사용량 수 ㎖ 내지 수백 ㎖ 정도에서 적절히 선택될 수 있다. 투여량 또는 섭취량은 조성물에 함유된 유효성분 및 다른 성분의 종류 및 함량, 제형의 종류 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료 기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다.The dosage or intake of the pharmaceutical composition of the present invention may be appropriately selected from about several hundred mg to several g per adult in the case of powder formulation, and about several ml to several hundred ml per adult in the case of solution. Dosage or intake depends on the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the age, weight, general health, sex and diet of the patient, time of administration, route of administration and rate of composition, duration of treatment This can be adjusted according to a variety of factors, including drugs used concurrently.

본 발명의 약제학적 조성물은 천연의 식품으로부터 추출되었으므로, 인체에 투약하는 경우에도 부작용을 나타내지 않는다.Since the pharmaceutical composition of the present invention is extracted from natural foods, it does not show side effects even when administered to the human body.

이렇게 하여 제조된 본 발명의 조성물은 녹차 폴리페놀 단독, 아스코르빈산 단독, 녹차 전체추출물 단독 또는 기존에 공지된 10% EGCG 조성물에 비해, 자외선조사에 의한 세포 광독성을 효율적으로 억제하여 세포활성비율을 현저하게 증가 시킨다.The composition of the present invention prepared in this way, compared to the green tea polyphenol alone, ascorbic acid alone, green tea whole extract alone or the 10% EGCG composition known in the prior art, it effectively inhibits the cell phototoxicity by UV irradiation to improve the cell activity ratio Increase significantly.

본 발명의 조성물의 피부 광 손상 억제 효과는 본 발명의 조성물이 함유하는 녹차 폴리페놀과, 아스코르빈산 또는 그 유도체들이 자외선 조사에 의해서 증가되는 세포내 반응성 유리기를 소거하기 때문에 나타나는 것으로 보인다.The effect of inhibiting skin light damage of the composition of the present invention appears to be due to the green tea polyphenols contained in the composition of the present invention and ascorbic acid or its derivatives eliminate intracellular reactive free groups that are increased by ultraviolet irradiation.

또한 본 발명의 조성물은 피부가 자외선에 노출되는 시점을 기준으로 하여 그 이전 또는 이후에 사용되는지의 여부에 상관없이, 모든 경우에서 우수한 광 손상 억제 효과를 나타낸다.In addition, the compositions of the present invention show excellent light damage inhibiting effects in all cases, whether or not used before or after the skin is exposed to ultraviolet light.

본 발명의 조성물을 자외선 노출 전에 사용할 경우 나타나는 광 손상 억제 기전은 다음과 같이 생각할 수 있다. 자외선 조사에 의한 세포손상작용은 자외선 조사 직후 시작되는 것으로 알려져 있다. 따라서, 본 발명의 조성물은 자외선 조사에 의한 세포독성작용의 개시를 예방함으로써, 자외선 조사에 의한 세포독성을 억제할 수 있는 것으로 보인다.The mechanism of suppressing light damage when the composition of the present invention is used prior to ultraviolet exposure can be considered as follows. Cell damage by UV irradiation is known to begin immediately after UV irradiation. Therefore, the composition of the present invention seems to be able to suppress the cytotoxicity by ultraviolet irradiation by preventing the onset of cytotoxic action by ultraviolet irradiation.

본 발명의 조성물을 자외선 노출 후에 사용할 경우 나타나는 광 손상 억제 기전은 다음과 같이 생각할 수 있다. 자외선에 노출된 후 30분 정도가 경과하면 자외선에 의한 세포 손상이 이미 진행되고 있는 상태이다. 따라서, 본 발명의 조성물은 자외선 조사에 의해 손상된 세포를 회복시킴으로써 자외선 조사에 의한 세포독성을 억제할 것으로 보인다.The mechanism of suppressing light damage when the composition of the present invention is used after ultraviolet exposure can be considered as follows. About 30 minutes after exposure to ultraviolet rays, cell damage by ultraviolet rays is already in progress. Therefore, the composition of the present invention is expected to suppress cytotoxicity by ultraviolet irradiation by repairing cells damaged by ultraviolet irradiation.

따라서, 본 발명의 조성물은 자외선에 의한 피부 광 손상을 억제하는 용도의 화장료, 식품 및 약제학적 조성물로 유용하게 사용될 수 있다.Therefore, the composition of the present invention can be usefully used as a cosmetic, food and pharmaceutical composition for the purpose of suppressing skin light damage by ultraviolet rays.

또한 본 발명은 상기 조성물을 섭취하거나 또는 피부에 도포하여 사용함으로써 피부 광 손상을 억제하는 방법을 함께 제공한다.The present invention also provides a method for suppressing skin light damage by ingesting the composition or applying it to the skin.

예로 본 발명의 피부 광 손상 억제용 식품 조성물 중 분말캡슐, 분말, 또는 마이크로캡슐 형태의 조성물을 사용할 경우, 캡슐이나 정제 등 적절한 형태로 만들어서 자외선 조사 전 또는 후에 1일 수백 - 수천mg을 사용하는 것이 바람직하다.For example, when using a composition of powder capsules, powders or microcapsules in the food composition for inhibiting skin light damage of the present invention, it is recommended to use a capsule or tablet in a suitable form such as hundreds to thousands of mg per day before or after UV irradiation. desirable.

예로 본 발명의 피부 광 손상 억제용 화장료 조성물 중 분말캡슐, 분말, 또는 마이크로캡슐 형태의 조성물을 사용할 경우, 사용 직전에 적정량의 캡슐 또는 분말을 소량의 물에 녹인다. 본 발명의 조성물 중 폴리페놀 성분은 물과 혼합된 후에는 시간이 경과함에 따라 활성이 서서히 감소되므로, 본 발명의 조성물을 물에 녹인 후에는 화장용 붓 등의 적절한 도구를 이용하여 사용부위에 신속하게 도포한다. 이 경우 1회 사용분은 1 - 10 g이며, 사용횟수는 주 2 - 3회인 것이 바람직하다.For example, in the case of using the composition of powder capsule, powder, or microcapsules in the cosmetic composition for inhibiting skin light damage of the present invention, a proper amount of capsule or powder is dissolved in a small amount of water immediately before use. Since the activity of the polyphenol component in the composition of the present invention gradually decreases with time after mixing with water, after dissolving the composition of the present invention in water, the polyphenol component can be quickly applied to a site of use using an appropriate tool such as a cosmetic brush. Apply. In this case, it is preferable that one use amount is 1-10 g, and the use frequency is 2-3 times a week.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.

[실시예] 본 발명의 조성물 제조EXAMPLES Preparation of the Composition of the Invention

본 발명의 조성물을 제조하면서, 비교예로 사용될 조성물도 함께 제조하였다. 비교예 1은 녹차 폴리페놀만으로 이루어진 시료, 비교예 2는 아스코르빈산만으로 이루어진 시료, 비교예 3은 녹차 전체 추출물로 이루어진 시료, 그리고 비교예4는 시판되는 폴리페놀(epigallocatechin gallate, 이하 EGCG라 한다, Cat. No. E4243, Sigma Chemical Co. USA)의 10% 수용액으로 이루어진 시료로 준비하였다.While preparing the composition of the present invention, a composition to be used as a comparative example was also prepared. Comparative Example 1 is a sample consisting of only green tea polyphenols, Comparative Example 2 is a sample consisting only of ascorbic acid, Comparative Example 3 is a sample consisting of the whole green tea extract, and Comparative Example 4 is a commercial polyphenol (epigallocatechin gallate, EGCG hereinafter) (C. No. E4243, Sigma Chemical Co. USA).

본 발명의 조성물은 녹차 폴리페놀 분말 900g과 아스코르빈산 100g을 혼합하여 제조하였다.The composition of the present invention was prepared by mixing 900 g of green tea polyphenol powder and 100 g of ascorbic acid.

본 발명의 조성물 및 비교예 1이 포함하는 녹차 폴리페놀 분말은 대한민국 등록특허공보 제 10-377313호에 기재되어 있는 녹차 추출물의 제조방법에 따라 추출, 분리, 정제하여 사용하였다.The green tea polyphenol powder included in the composition of the present invention and Comparative Example 1 was used by extracting, separating and purifying according to the preparation method of the green tea extract described in Korean Patent Publication No. 10-377313.

정제된 추출물에 녹차 폴리페놀이 다량 함유되어있는지 확인하기 위해, 상기 추출물에 대해 다음과 같이 성분 분석을 수행하였다.In order to check whether the purified extract contains a large amount of green tea polyphenols, component analysis was performed on the extract as follows.

각 폴리페놀과 카페인은 HPLC(high performance liquid chromatography)법, 전체 폴리페놀은 프러시안 블루(Prussian blue)법에 의한 분광학적 산화환원 분석법(Spectrophotometric redox assay)에 의해 측정한 결과, 본 실시예에서 얻은 녹차 폴리페놀 분말은 폴리페놀을 83% 이상 함유하는 것으로 나타났다. 상기와 같은 순도는 순수한 폴리페놀의 물리적ㆍ화학적 특성을 나타내기에 충분한 수준이다.Each polyphenol and caffeine were measured by HPLC (high performance liquid chromatography), and the total polyphenols were measured by Spectrophotometric redox assay using Prussian blue. Green tea polyphenol powder was found to contain at least 83% polyphenols. Such purity is sufficient to show the physical and chemical properties of pure polyphenols.

본 발명의 조성물 및 비교예 2가 포함하는 아스코르빈산은 미국 Sigma사(A5960)에서 시판하는 제품을 사용하였다.Ascorbic acid included in the composition of the present invention and Comparative Example 2 was used a product sold by the US Sigma (A5960).

비교예 3은 열풍건조한 녹차잎 분말 1 중량부에 5∼20(정확한 수치 필요) 중량부의 물을 가하여 1시간 동안 가열한 후, 녹차잎 분말을 제거하고 건조시켜 제조하였다.Comparative Example 3 was prepared by adding 5 to 20 parts by weight of water to 1 part by weight of hot-air-dried green tea leaf powder and heating it for 1 hour, followed by removing and drying the tea leaf powder.

비교예 4는 0.1㎎ EGCG를 증류수에 용해시켜 1㎖ 수용액이 되도록 함으로써10% EGCG용액을 제조하였다.In Comparative Example 4, a 10% EGCG solution was prepared by dissolving 0.1 mg EGCG in distilled water to make a 1 ml aqueous solution.

[실험예 1] 본 발명의 조성물의 광 손상 예방 효과 확인 - 본 발명의 조성물 첨가 후 자외선 조사시 세포활성의 변화[Experimental Example 1] Confirmation of light damage prevention effect of the composition of the present invention-Change of cell activity upon ultraviolet irradiation after addition of the composition of the present invention

본 발명의 조성물의 광 손상 예방 효과를 확인하기 위해, 본 발명의 조성물 첨가 후 자외선 조사시 세포활성의 변화를 관찰하였다.In order to confirm the effect of preventing light damage of the composition of the present invention, the change of cell activity was observed upon ultraviolet irradiation after addition of the composition of the present invention.

실험에 사용될 사람의 피부 세포는 다음과 같이 준비하였다.Human skin cells to be used in the experiment were prepared as follows.

사람의 귀두 피부를 절제하여 냉각된 PBS(phosphate buffered saline; Gibco. USA)로 세척한 후 trypsin(Gibco. USA) 처리하여 각질세포(keratinocytes)를 분리하였다. 분리된 각질세포를 96 웰 세포배양용기(96 well plate)에 한 웰당 2 ×105개씩 심은 후, 무혈청 각질세포 배양액(serum-free keratinocytes medium, Gibco. USA)을 첨가하고, 37℃가 유지되는 CO2배양기에서 배양하였다.Human glans were excised and washed with cooled PBS (Phosphate buffered saline; Gibco. USA) and then treated with trypsin (Gibco. USA) to separate keratinocytes. Isolated keratinocytes are planted in 96 well plate (96 well plate) 2 × 10 5 per well, and then serum-free keratinocytes medium (Gibco. USA) is added and maintained at 37 ° C. Were incubated in a CO 2 incubator.

세포배양 1일 후, 상기 실시예에서 제조한 본 발명의 조성물 및 대조군 시료를 각각 0, 0.025, 0.05, 0.1, 0.2, 0.5, 1, 2, 4㎎/㎖의 농도가 되도록 세포배양액에 첨가하였다.After 1 day of cell culture, the composition and the control sample of the present invention prepared in the above examples were added to the cell culture solution to a concentration of 0, 0.025, 0.05, 0.1, 0.2, 0.5, 1, 2, 4 mg / ml, respectively. .

각 시료를 첨가한지 30분 후 각 군에 자외선을 조사하였다. 자외선은 300㎚ 파장의 UVB 램프를 이용하여 50 J/㎠가 되도록 조사하였다. 이때 자외선 조사를 시행하지 않은 군도 따로 준비하여, 이후에 자외선 조사군에 대한 세포활성 비율을 비교하는 정상대조군으로 이용하였다.30 minutes after the addition of each sample, each group was irradiated with ultraviolet rays. Ultraviolet rays were irradiated to 50 J / cm 2 using a 300 nm wavelength UVB lamp. At this time, the group not subjected to ultraviolet irradiation was prepared separately, and then used as a normal control group comparing the cell activity ratio with respect to the ultraviolet irradiation group.

세포를 각 시료가 첨가된 배양액으로 교환하고 30분 경과 후 자외선을 조사하여, 37℃가 유지되는 CO2배양기에서 24시간 동안 배양한 후 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide)법으로 세포활성(cell viability)을 측정하여, 자외선 조사를 하지 않은 실험군의 세포활성에 대한 비율로 환산하여 표 1에 나타내었다.Exchange cells into the culture medium of each sample was added and after 30 minutes, and then irradiated with ultraviolet rays, cultured in a CO 2 incubator that 37 ℃ maintained for 24 hours MTT (3- (4,5-dimethylthiazol- 2-yl) Cell viability was measured by the method of -2,5-diphenyl-tetrazolium bromide), and the results are shown in Table 1 in terms of the ratio of the cell activity of the experimental group that was not irradiated with ultraviolet light.

피부 각질세포 배양액에 각 시료를 첨가한지 30분 후 자외선 조사가 세포 활성에 미치는 영향Effect of Ultraviolet Irradiation on Cell Activity after 30 Minutes of Addition of Samples to Skin Keratinocyte Cultures 조성물농도(㎎/㎖)Composition concentration (mg / ml) 세포활성 비율(%)% Of cell activity 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 비교예 4Comparative Example 4 실시예Example 녹차 폴리페놀시료 첨가군Green tea polyphenol sample addition group 아스코르브산시료 첨가군Ascorbic acid sample addition group 전체녹차추출물시료 첨가군Addition of whole green tea extract sample 10% EGCG시료 첨가군10% EGCG sample added group 본 발명의조성물 첨가군Composition addition group of the present invention 00 2222 2525 2525 2424 2424 0.050.05 2929 3232 2525 2525 3535 0.10.1 4646 2828 3434 2424 8787 0.20.2 5757 2121 4545 2525 9898 0.50.5 7373 1010 5252 2525 101101 1One 6565 1111 5151 3131 9898 22 2828 77 3232 4343 7474

(수치 = 평균값)(Num = average)

표 1에 나타난 바와 같이, 본 발명의 조성물을 첨가한 군은 조성물의 농도가 증가됨에 따라 세포활성이 증가되었다. 특히 본 발명의 조성물을 0.5㎎/㎖의 농도로 처리하였을 때, 세포 활성은 조성물을 처리하지 않은 경우(0㎎/㎖)에 비해 77%까지 증가되었다.As shown in Table 1, the group to which the composition of the present invention was added increased cell activity as the concentration of the composition was increased. In particular, when the composition of the present invention was treated at a concentration of 0.5 mg / ml, the cell activity was increased by 77% compared to the non-treated composition (0 mg / ml).

녹차 폴리페놀 시료만을 첨가한 군에서도 시료의 농도가 증가됨에 따라 세포활성이 증가되었으나, 본 발명의 조성물과 비교할 때 그 효과가 미약하였다. 상기 시료를 0.5㎎/㎖의 농도로 처리하였을 때, 세포 활성은 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 51% 증가하였으며, 그 이후에는 농도를 증가시켜도 세포활성은 감소하였다.In the group in which only the green tea polyphenol sample was added, the cell activity increased as the concentration of the sample was increased, but the effect was weak compared to the composition of the present invention. When the sample was treated at a concentration of 0.5 mg / ml, the cell activity was increased by 51% compared to the case where the sample was not treated (0 mg / ml), after which the cell activity was decreased even by increasing the concentration.

아스코르빈산 분말만을 첨가한 군에서도 시료의 농도가 증가됨에 따라 세포활성이 증가되었으나, 본 발명의 조성물과 비교할 때 그 효과가 매우 미약하였다. 상기 시료를 0.5㎎/㎖의 농도로 처리하였을 때, 세포 활성은 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 7%가 증가되는 수준에 그쳤으며, 그 이후에는 농도를 증가시켜도 세포활성은 감소하였다.In the group to which only ascorbic acid powder was added, the cell activity increased as the concentration of the sample was increased, but the effect was very weak compared to the composition of the present invention. When the sample was treated at a concentration of 0.5 mg / ml, the cell activity was only 7% higher than that without the sample (0 mg / ml), after which the cell activity was increased even if the concentration was increased. Decreased.

전체 녹차 추출물 분말만을 첨가한 군에서도 시료의 농도가 증가됨에 따라 세포활성이 증가되었으나, 본 발명의 조성물과 비교할 때 그 효과가 미약하였다. 상기 시료를 0.5㎎/㎖의 농도로 처리하였을 때, 세포 활성은 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 27% 증가하였으며, 그 이후에는 농도를 증가시켜도 세포활성은 감소하였다.In the group to which only the whole green tea extract powder was added, the cell activity increased as the concentration of the sample increased, but the effect was weak compared to the composition of the present invention. When the sample was treated at a concentration of 0.5 mg / ml, the cell activity was increased by 27% compared to the case where the sample was not treated (0 mg / ml), after which the cell activity was decreased even by increasing the concentration.

10% EGCG 용액을 첨가한 군에서는 시료가 1㎎/㎖와 2㎎/㎖의 농도로 처리되었을 때 세포활성이 7% 및 19% 증가하였으나, 같은 농도로 본 발명의 조성물을 처리한 군에서 나타나는 74% 및 50%와 비교할 때 그 효과가 매우 미약하였다.In the group to which the 10% EGCG solution was added, the cell activity increased by 7% and 19% when the samples were treated at the concentrations of 1 mg / ml and 2 mg / ml. Compared to 74% and 50%, the effect was very slight.

각 군간의 세포활성 증가율을 비교해 볼 때, 본 발명의 조성물 첨가군은 녹차 폴리페놀 조성물 첨가군보다 26%, 아스코르빈산 조성물 첨가군보다 70%, 녹차 전체추출물 조성물 첨가군보다 50%, 10% EGCG 첨가군보다 76%가 각각 증가된 세포활성을 나타내었다.Comparing the increase rate of cell activity between the groups, the composition added group of the present invention is 26% than the green tea polyphenol composition added group, 70% than the ascorbic acid composition added group, 50%, 10% than the green tea total extract composition added group 76% increased cell activity than EGCG addition group.

따라서, 본 발명의 조성물은 자외선 노출 전에 적용하면 기존의 피부 광 손상 억제물질에 비해 자외선에 의한 피부세포독성을 효과적으로 억제할 수 있다.Therefore, the composition of the present invention can effectively inhibit skin cytotoxicity caused by ultraviolet rays when applied before exposure to ultraviolet rays as compared to conventional skin light damage inhibitors.

또한 상기와 같은 본 발명의 조성물을 첨가하고 자외선을 자외선 조사하여 세포독성이 감소되므로, 본 발명의 조성물이 자외선 조사에 의한 세포독성작용의 개시를 예방함으로써 자외선 조사에 의한 세포독성을 억제하기 때문에 나타나는 것으로 보인다.In addition, since the cytotoxicity is reduced by adding the composition of the present invention as described above and irradiating ultraviolet rays, the composition of the present invention is suppressed by inhibiting the cytotoxicity caused by ultraviolet irradiation by preventing the onset of cytotoxic action by ultraviolet irradiation. Seems to be.

[실험예 2] 본 발명의 조성물의 광 손상 치료 효과 확인 - 자외선 조사 후[Experimental Example 2] Confirm the light damage treatment effect of the composition of the present invention-after ultraviolet irradiation 본 발명의 조성물 첨가시 세포활성의 변화Changes in Cell Activity Upon Addition of the Composition of the Present Invention

본 발명의 조성물의 광 손상 치료 효과를 확인하기 위해, 자외선 조사 후 본 발명의 조성물 첨가시 세포활성의 변화를 관찰하였다.In order to confirm the photodamage treatment effect of the composition of the present invention, the change of cell activity was observed upon addition of the composition of the present invention after ultraviolet irradiation.

실험에 사용될 사람의 피부 세포는 상기 실험예 1과 같이 준비하였다.Human skin cells to be used in the experiment were prepared as in Experimental Example 1.

세포배양 1일 후, 세포에 자외선을 조사하였다. 자외선 조사는 300㎚ 파장의 UVB 램프를 이용하여 50 J/㎠가 되도록 시행하였다. 이때 자외선 조사를 시행하지 않은 세포들도 따로 준비하여, 이후에 세포활성 비율을 비교할 수 있도록 하였다.One day after cell culture, the cells were irradiated with ultraviolet rays. Ultraviolet irradiation was carried out to 50 J / ㎠ using a UVB lamp of 300nm wavelength. At this time, cells that were not subjected to UV irradiation were also prepared separately, so that the cell activity ratios could be compared later.

자외선을 조사한지 30분 후, 세포 배양액을 상기 실시예에서 제조한 본 발명의 조성물 및 각 대조군 시료가 첨가된 배양액으로 교환하였다. 이때 배양액에는 각각의 시료가 0, 0.025, 0.05, 0.1, 0.2, 0.5, 1, 2, 4㎎/㎖의 농도로 함유되도록 하였다.After 30 minutes of ultraviolet irradiation, the cell culture was exchanged with the culture of the composition of the present invention prepared in the above examples and each control sample added thereto. At this time, each sample was contained at concentrations of 0, 0.025, 0.05, 0.1, 0.2, 0.5, 1, 2, 4 mg / ml.

각 군의 세포를 37℃가 유지되는 CO2배양기에서 24시간 동안 배양한 후, MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide)법으로 세포활성(cell viability)을 측정하고, 자외선 조사를 하지 않은 실험군의 세포활성에 대한 비율로 환산하여 표 2에 나타내었다.After incubating the cells of each group for 24 hours in a CO 2 incubator maintained at 37 ℃, MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide) method (cell viability) was measured, and converted to the ratio of the cell activity of the experimental group not irradiated with ultraviolet rays are shown in Table 2.

피부각질세포에 자외선 조사 30분 후 각 시료 첨가시 세포 활성에 미치는 영향Effect of each sample after 30 minutes of UV irradiation on keratinocytes 조성물농도(㎎/㎖)Composition concentration (mg / ml) 세포활성 비율(%)% Of cell activity 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 비교예 4Comparative Example 4 실시예Example 녹차 폴리페놀시료 첨가군Green tea polyphenol sample addition group 아스코르브산시료 첨가군Ascorbic acid sample addition group 전체녹차추출물시료 첨가군Addition of whole green tea extract sample 10% EGCG시료 첨가군10% EGCG sample added group 본 발명의조성물 첨가군Composition addition group of the present invention 00 2323 2323 2222 2323 2424 0.050.05 2929 3131 2626 2424 3737 0.10.1 3838 2323 3333 2323 5757 0.20.2 5555 1010 3535 2525 7878 0.50.5 5151 88 4141 2525 7272 1One 3232 1111 3838 2929 4949

(수치 = 평균값)(Num = average)

표 2에 나타난 바와 같이, 본 발명의 조성물을 첨가한 군에서는 조성물의 농도가 증가됨에 따라 세포활성이 증가되었다. 특히 본 발명의 조성물을 0.2㎎/㎖의 농도로 처리하였을 때, 세포 활성은 조성물을 처리하지 않은 경우(0㎎/㎖)에 비해 54%까지 증가되었다.As shown in Table 2, in the group to which the composition of the present invention was added, cell activity increased as the concentration of the composition was increased. In particular, when the composition of the present invention was treated at a concentration of 0.2 mg / ml, the cell activity was increased by 54% compared to the non-treated composition (0 mg / ml).

녹차 폴리페놀 분말만을 첨가한 군에서도 시료의 농도가 증가됨에 따라 세포활성이 증가되었으나, 본 발명의 조성물과 비교할 때 그 효과가 미약하였다. 상기 시료를 0.2㎎/㎖의 농도로 처리하였을 때, 세포 활성은 조 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 32% 증가하였으며, 그 이후에는 농도를 증가시켜도 세포활성은 감소하였다.In the group to which only the green tea polyphenol powder was added, the cell activity increased as the concentration of the sample was increased, but the effect was weak compared to the composition of the present invention. When the sample was treated at a concentration of 0.2 mg / ml, the cell activity was increased by 32% compared to the case where the crude sample was not treated (0 mg / ml), after which the cell activity was decreased even by increasing the concentration.

아스코르빈산 분말만을 첨가한 군에서도 시료의 농도가 증가됨에 따라 세포활성이 증가되었으나, 본 발명의 조성물과 비교할 때 그 효과가 매우 미약하였다. 상기 시료를 0.2㎎/㎖의 농도로 처리하였을 때, 세포 활성은 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 8%가 증가되는 수준에 그쳤으며, 그 이후에는 농도를 증가시켜도 세포활성은 감소하였다.In the group to which only ascorbic acid powder was added, the cell activity increased as the concentration of the sample was increased, but the effect was very weak compared to the composition of the present invention. When the sample was treated at a concentration of 0.2 mg / ml, the cell activity was only 8% higher than that without the sample (0 mg / ml), after which the cell activity was increased even if the concentration was increased. Decreased.

녹차 전체추출물 분말만을 첨가한 군에서도 시료의 농도가 증가됨에 따라 세포활성이 증가되었으나, 본 발명의 조성물과 비교할 때 그 효과가 미약하였다. 상기 시료를 0.2㎎/㎖의 농도로 처리하였을 때, 세포 활성은 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 19% 증가하였으며, 그 이후에는 농도를 증가시켜도 세포활성은 감소하였다.In the group containing only green tea extract powder, the cell activity was increased as the concentration of the sample was increased, but the effect was weak compared to the composition of the present invention. When the sample was treated at a concentration of 0.2 mg / ml, the cell activity increased by 19% compared to the case where the sample was not treated (0 mg / ml), after which the cell activity was decreased even by increasing the concentration.

10% EGCG 용액을 첨가한 군에서는 시료를 1㎎/㎖ 이상의 농도로 처리해야만 시료를 처리하지 않은 경우(0㎎/㎖)에 비해 세포활성이 5% 증가하는 수준에 그쳐, 본 발명의 조성물과 비교할 때 그 효과가 매우 미약하였다.In the group to which the 10% EGCG solution was added, the sample had to be treated at a concentration of 1 mg / ml or more, and the cell activity increased by 5% compared to the case where the sample was not treated (0 mg / ml). In comparison, the effect was very weak.

각 군간의 세포활성 증가율을 비교해 볼 때, 본 발명의 조성물 첨가군은 녹차 폴리페놀 조성물 첨가군보다 23%, 아스코르빈산 조성물 첨가군보다 47%, 녹차 전체추출물 조성물 첨가군보다 31%, 10% EGCG 용액 조성물 첨가군보다 53%가 각각 증가된 세포활성을 나타내었다.Comparing the increase rate of cell activity between the groups, the composition added group of the present invention is 23% than the green tea polyphenol composition added group, 47% than the ascorbic acid composition added group, 31%, 10% than the green tea total extract composition added group The cell activity was increased by 53% than the EGCG solution composition addition group.

따라서, 본 발명의 조성물은 자외선에 노출된 후 적용하면 기존의 피부 광 손상 억제물질에 비해 피부세포독성을 효과적으로 억제할 수 있다.Therefore, the composition of the present invention can effectively inhibit skin cytotoxicity when applied after exposure to ultraviolet rays as compared to conventional skin light damage inhibitors.

또한 상기와 같은 본 발명의 조성물의 광 손상 억제 효과는 세포에 자외선을 조사하면 즉시 세포손상이 시작되어 자외선 조사 후 30분이 경과된 시점은 이미 자외선에 의한 세포 손상이 진행된 상태라는 점에서, 본 발명의 조성물이 자외선 조사에 의해서 이미 손상된 세포를 회복시킴으로써 자외선 조사에 의한 세포독성을 억제하기 때문에 나타나는 것으로 보인다.In addition, the light damage inhibiting effect of the composition of the present invention as described above is that when cell is irradiated with UV rays, cell damage starts immediately, and 30 minutes after the UV irradiation, the cell damage by UV rays is already in progress. It appears that the composition of inhibits the cytotoxicity caused by ultraviolet irradiation by restoring cells already damaged by ultraviolet irradiation.

본 발명의 조성물은 자외선 조사에 의한 세포 손상의 시작 단계를 억제하고 자외선 조사에 의해 이미 손상된 세포를 회복시키는 효과가 기존의 피부 광 손상 억제용 조성물에 비해 매우 우수하다.The composition of the present invention has a very excellent effect of suppressing the onset of cell damage caused by ultraviolet radiation and restoring cells already damaged by ultraviolet radiation as compared with the conventional composition for inhibiting skin light damage.

본 발명의 조성물의 광 손상 억제 효과는 자외선 조사 전 또는 조사 후의 여부에 상관없이 모든 경우에서 우수하게 나타난다.The light damage inhibiting effect of the composition of the present invention is excellent in all cases regardless of whether it is before or after ultraviolet irradiation.

따라서, 본 발명의 조성물은 자외선에 의한 피부 광 손상을 억제하는 용도의 화장료, 식품 및 약제학적 조성물로 유용하게 사용될 수 있다.Therefore, the composition of the present invention can be usefully used as a cosmetic, food and pharmaceutical composition for the purpose of suppressing skin light damage by ultraviolet rays.

Claims (10)

녹차 폴리페놀 50∼95 중량부와, 아스코르빈산 또는 그 유도체 5∼50 중량부로 이루어진 피부 광 손상 억제용 조성물50-95 parts by weight of green tea polyphenols and 5-50 parts by weight of ascorbic acid or derivatives thereof. 제 1항에 있어서, 폴리페놀은 에피갈로카테친 갈레이트(epigallocatechin gallate), 에피카테친 갈레이트(epicatechine gallate), 에피갈로카테친(epigallocatechine) 중에서 선택된 하나 이상임을 특징으로 하는 피부 광 손상 억제용 조성물The composition of claim 1, wherein the polyphenol is at least one selected from epigallocatechin gallate, epicatechin gallate, and epigallocatechin. 제 1항 또는 제 2항에 있어서, 아스코르빈산 또는 그 유도체는 아스코르빈산(ascorbic acid), 아스코르빌 팔미테이트(ascorbyl palmitate), 칼슘 아스코르베이트(calcium ascorbates), 마그네슘 아스코르베이트(magnesium ascorbates) 및 아연 아스코르베이트(zinc ascorbates) 중에서 선택된 하나 이상임을 특징으로 하는 피부 광 손상 억제용 조성물The method of claim 1 or 2, ascorbic acid or derivatives thereof are ascorbic acid (ascorbic acid), ascorbyl palmitate, calcium ascorbates (calcium ascorbates), magnesium ascorbate (magnesium) ascorbates) and zinc ascorbates (zinc ascorbates) at least one selected from the composition for inhibiting skin light damage 제 3항에 있어서, 자외선에 의한 세포독성을 억제하는 피부 광 손상 억제용 조성물The composition for inhibiting skin light damage according to claim 3, which inhibits cytotoxicity caused by ultraviolet rays. 제 4항에 있어서, 자외선에 의한 세포독성작용의 개시를 예방하는 피부 광손상 억제용 조성물The composition for inhibiting skin photodamage according to claim 4, which prevents the onset of cytotoxic action by ultraviolet rays. 제 4항에 있어서, 자외선 조사에 의해서 손상된 세포를 회복시키는 피부 광 손상 억제용 조성물The composition for inhibiting skin light damage according to claim 4, which recovers cells damaged by ultraviolet irradiation. 제 4항 내지 제 6항 중 어느 한 항에 있어서, 화장료 조성물, 식품 조성물, 또는 약제학적 조성물임을 특징으로 하는 피부 광 손상 억제용 조성물The composition for inhibiting skin light damage according to any one of claims 4 to 6, which is a cosmetic composition, a food composition, or a pharmaceutical composition. 제 7항에 있어서, 분말캡슐, 분말, 또는 마이크로캡슐로 이루어짐을 특징으로 하는 피부 광 손상 억제용 조성물According to claim 7, wherein the composition for inhibiting skin light damage, characterized in that consisting of powder capsules, powders, or microcapsules 제 8항의 조성물을 섭취하거나 또는 피부에 도포하여 사용함을 특징으로 하는 피부 광 손상 억제 방법Method of inhibiting skin light damage, characterized by ingesting the composition of claim 8 or applying it to the skin 제 9항에 있어서, 제 8항의 조성물을 사용 직전에 소량의 물에 갠 후, 사용부위에 도포함을 특징으로 하는 피부 광 손상 억제 방법10. The method for inhibiting skin light damage according to claim 9, wherein the composition of claim 8 is poured into a small amount of water immediately before use, and then applied to the used area.
KR1020030047504A 2003-07-12 2003-07-12 Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives KR20050007883A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020030047504A KR20050007883A (en) 2003-07-12 2003-07-12 Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives
PCT/KR2004/001524 WO2005004827A1 (en) 2003-07-12 2004-06-24 Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020030047504A KR20050007883A (en) 2003-07-12 2003-07-12 Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives

Publications (1)

Publication Number Publication Date
KR20050007883A true KR20050007883A (en) 2005-01-21

Family

ID=34056818

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020030047504A KR20050007883A (en) 2003-07-12 2003-07-12 Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives

Country Status (2)

Country Link
KR (1) KR20050007883A (en)
WO (1) WO2005004827A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH697437B1 (en) * 2005-11-02 2008-10-15 Omnimedica Ag Means for the protection of body cells.
ITMI20080560A1 (en) * 2008-04-01 2009-10-02 Lodovico Gianluca Braguti PREVENTIVE-PROTECTIVE COMPOSITIONS AGAINST THE ABSENCE OF CUTANEOUS PHOTOALLERGIC AND PHOTOTOSSIC MANIFESTATIONS
CN109620788B (en) * 2019-01-30 2022-03-25 周忠平 Tea polyphenol extraction process and application thereof in beauty and whitening liquid
CN111803410B (en) * 2020-06-03 2022-06-24 浙江农林大学 Pure natural woody plant extract and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162419A (en) * 1996-11-26 2000-12-19 Nicholas V. Perricone Stabilized ascorbyl compositions
KR100265089B1 (en) * 1997-12-29 2000-11-01 서경배 Cosmetic or pharmaceutical composition having protecyive effects of green tea polyphenols
DE19827624A1 (en) * 1998-06-20 1999-12-23 Beiersdorf Ag Use of catechols or plant extracts containing them in intensifying natural skin tanning or in stimulating melanogenesis
AU2000258901A1 (en) * 2000-04-06 2001-10-23 Nicholas V. Perricone Treatment of skin damage using olive oil polyphenols

Also Published As

Publication number Publication date
WO2005004827A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
KR101224697B1 (en) Bioactive compositions from theacea plants and processes for their production and use
KR101677254B1 (en) Composition for beauty of skin containing coumestrol or germinated soy bean extract with coumestrol
KR100825450B1 (en) Skin anti-wrinkle cosmetics composition containing Forsythiae Fruit extract
US8911774B2 (en) Topical composition for anti-aging skin treatment using dual DNA repair mechanism and method of use
EP1841404A1 (en) Skin-condition improving composition comprising vaccinium uliginosum extract and method for preparation thereof
KR100795512B1 (en) Skin care composition comprising the extract of Centella asiatica and Magnolia kobus
KR101382112B1 (en) Composition of skin external application containing Chamaecyparis obtusa polysaccharide
KR102525467B1 (en) Skin external application composition for anti-aging containing Rhodotypos scandens extract
KR100742267B1 (en) Extract of Chrysanthemum morifolium Ramat, the preparation method thereof and the cosmetic composition comprising the same for whitening
KR20220112447A (en) Composition for improving skin, comprising Elaeaqnus macrophylla Extract as effective components, Cosmetic composition and Food functional composition including the same
KR102525901B1 (en) Skin external application composition for anti-aging containing Phlox subulata extract
KR102277525B1 (en) Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising fargesin
KR20050007883A (en) Composition for anti-phototoxic effect on skin comprising polyphenol purified from green tea, and ascorbic acid and its derivatives
KR101223684B1 (en) Compositions for Improving Skin Conditions Comprising Afzelin as an Active Ingredient
KR102322441B1 (en) Composition for skin whitening containing an extract derived from a petiole of Green tea
KR102348149B1 (en) Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising parthenolide
KR102155246B1 (en) Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex
KR102272476B1 (en) Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising isopimpinellin
KR102628074B1 (en) skin external application composition for anti-aging containing Luzula capitate extract
KR102104305B1 (en) Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising monomyristin or a pharmaceutically acceptable salt thereof
KR102348148B1 (en) Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising dihydroartemisinin
US20210030654A1 (en) Antioxidant complex and composition for forming same
KR100930592B1 (en) Skin whitening and antioxidant composition containing extracts against
KR20220112448A (en) Composition for improving skin, comprising Phellinus ribis Extract as effective components, Cosmetic composition and Food functional composition including the same
KR102272475B1 (en) Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising pimpinellin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application